NCT04402970View on ClinicalTrials.gov

Dornase Alfa for ARDS in Patients With Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2)

PHASE3CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

June 19, 2020

Primary Completion Date

December 31, 2020

Study Completion Date

December 31, 2020

Conditions
SARS-CoV 2ARDS
Interventions
DRUG

Dornase Alfa Inhalation Solution

Nebulized dornase alfa

Trial Locations (1)

65212

University of Missouri Hospital and Clinics, Columbia

All Listed Sponsors
lead

University of Missouri-Columbia

OTHER

NCT04402970 - Dornase Alfa for ARDS in Patients With Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) | Biotech Hunter | Biotech Hunter